Search

Displaying results 2791 - 2800 of 4300 in total
  1. Drug

    Sulodexide

    go.drugbank.com/drugs/DB06271
    ApprovedInvestigationalWithdrawn

    Sulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).

  2. Drug

    Smilagenin

    go.drugbank.com/drugs/DB05450
    Investigational

    Smilagenin is a novel non-peptide, orally bioavailable neurotrophic factor inducer that readily reverses free radical neurotoxicity produced by 1-ethyl-4- phenylpyridium (MPP+) in dopaminergic neurones … P58 is a protein synthesis stimulant acts by restoring levels of proteins that are altered in the ageing brain, reversing the loss of nerve receptors in the ageing brain and potentially allowing for the

  3. Drug

    Metocurine

    go.drugbank.com/drugs/DB01336
    Approved

    Dimethyltubocurarinium (INN) or metocurine (USAN), also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant. Patients on chronic anticonvulsant drugs are relatively resistant to metocurine.

  4. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  5. Drug

    Atinumab

    go.drugbank.com/drugs/DB17923
    Investigational

    ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.

  6. Drug

    KDT-3594

    go.drugbank.com/drugs/DB17085
    Investigational

    KDT-3594 is a non-ergot dopamine receptor agonist developed by Kissei Pharmaceutical.

  7. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 ...

  8. Drug

    AM103

    go.drugbank.com/drugs/DB05225
    Experimental

    It is being developed by Amira. … AM103 is a novel inhibitor of 5-lipoxygenase-activiting protein (FLAP) that has demonstrated potential to treat asthma and cardiovascular disease by preventing the synthesis of LT, which triggers inflammation

  9. Drug

    AC3056

    go.drugbank.com/drugs/DB05230
    Experimental

    It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials. … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals.

  10. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … previously developed COVID-19 monoclonal antibody treatments - including [bamlanivimab], [etesevimab], [casirivimab], and [imdevimab] - which have been found ineffective in the treatment of COVID-19 caused by